NCT02170012

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Repeat Doses Of Pf-06743649 In Healthy Elderly Subjects

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 65 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study in healthy elderly people is to evaluate safety, toleration and time course of plasma concentration of multiple oral doses of PF-06743649- The pharmacodynamic activity of PF-06743649 will also be assessed.

Conditions

• Healthy Elderly

Interventions

Type	Name	Description
DRUG	PF-06743649	20 mg tablet once daily dosing for 14 days
DRUG	Placebo	Placebo tablet once daily dosing for 14 days
DRUG	PF-06743649	To be decided dose, tablet once daily dosing for 14 days
DRUG	Placebo	Placebo tablet once daily dosing for 14 days
DRUG	PF-06743649	To be decided dose, tablet once daily dosing for 14 days
DRUG	Placebo	Placebo tablet once daily dosing for 14 days
DRUG	PF-06743649	To be decided dose, tablet once daily dosing for 14 days
DRUG	Placebo	Placebo tablet once daily dosing for 14 days
DRUG	PF-06743649	To be decided dose, tablet once daily dosing for 14 days
DRUG	Placebo	Placebo tablet once daily dosing for 14 days

Timeline

• Start date: 2014-07-01
• Primary completion: 2014-09-01
• Completion: 2014-09-01
• First posted: 2014-06-23
• Last updated: 2015-03-17

Locations

2 sites across 1 country: United States